Light-Activated implant could revolutionize arm fracture repair

NCT ID NCT02394080

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests a new device called the Photodynamic Bone Stabilization System for treating fractures of the humerus (the upper arm bone). The device is inserted into the bone and hardened with light to hold the broken pieces in place. Researchers are checking how well it helps bones heal and align properly in adults aged 50 and older with acute humerus fractures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a photodynamic bone stabilization system (a device that uses light to harden a stabilizing material inside the bone)
What this could lead to
If successful, this device could offer a less invasive way to stabilize humerus fractures, potentially leading to faster recovery and fewer complications.
What could go wrong
This is a small, early-stage study with only 44 participants, so results may not apply to everyone. Risks include infection, device failure, or incomplete bone healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Start date

Feb 2015

Finished

Jan 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Fracture-Specific Inclusion Criteria 1. Radiograph-confirmed diagnosis of acute, single isolated fracture of the humerus. AO classification 11A2, 11A3 and 11B1, 11B2 and 12A1, 12A2, 12A3 and 12B1, 12B2 (The Netherlands); AO Classification 11A1, 11A2, 11A3 and 11B1, 11B2 and 12A1, 12A2, 12A3 and 12B1, 12B2 and 13A1, 13A2 and 13B1, 13B2 (Germany). 2. Fracture is closed, Gustilo Type I or II. General Inclusion Criteria 3. Skeletally mature men and women, 50 years of age or older (The Netherlands only) or 61 years of age or older (Germany only) at time of index injury. 4. a) Female patients of child bearing potential agree to use double barrier method of contraception (The Netherlands only) b) Female patients of non-child bearing potential must meet one of the following criteria (The Netherlands only): * Postmenopausal for at least 1 year, or * Documented oophorectomy or hysterectomy, or * Surgically sterile 5. Willing and able to understand and sign the informed consent. Fracture-Specific Exclusion Criteria 1. Index treatment is greater than 28 days (The Netherlands only) or 14 days (Germany only) post fracture 2. Open fractures with severe contamination. 3. Extremely comminuted fractures where insufficient holding power of the balloon on the intramedullary canal is probable. 4. Marked bone loss or bone resorption patients, who due to a prior delayed union or non-union of the bones or other illnesses, may not be able to have their fracture adequately reduced prior to placement of the IlluminOss-device. This could leave bone void spaces that would preclude the device from maintaining alignment of the fractured bone. 5. Previous fracture of affected limb. General Exclusion Criteria 6. Pregnant or lactating (The Netherlands only). 7. Patients with a contralateral fracture of the forearm or humerus (Germany only). 8. Active or incompletely treated infections that could involve the site where the device will be implanted. 9. Distant foci of infections that may spread to the implant site 10. Uncooperative patients or patients, who are incapable of following directions (for example as a consequence of a neurological or psychiatric disorder). 11. Concomitant metabolic disorders that may impair bone formation. 12. Osteomalacia. 13. Allergic to implant materials or dental glue. 14. Vascular insufficiency, muscular atrophy, or neuro-muscular disease. 15. Polytrauma patients (multiple injuries resulting from a high-impact event, eg- a motor vehicle accident). 16. Life expectancy less than one year due to concurrent illness.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute humerus fractures are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Albert Schweitzer Hospital

    Dordrecht, 3318 AT, Netherlands

  • Amphia Hospital

    Breda, 4818 CK, Netherlands

  • Klinikum Oberberg GmbH

    Gummersbach, 51643, Germany

  • Lahn-Dill Kliniken

    Wetzlar, 35578, Germany

  • St. Vinzenz-Hospital GmbH

    Cologne, D-50733, Germany

  • University Hospital Maastricht

    Maastricht, 6229 HX, Netherlands